|
|
|
|
| LEADER |
01615nam a2200301 u 4500 |
| 001 |
EB001999918 |
| 003 |
EBX01000000000000001162819 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Clinical review report: Teduglutide (Revestive) (Shire Pharmaceuticals Ireland Limited)
|h Elektronische Ressource
|b indication: treatment of adults and pediatric patients one year of age and above with short bowel syndrome who are dependent on parenteral support
|
| 246 |
3 |
1 |
|a Teduglutide (Revestive) (Shire Pharmaceuticals Ireland Limited)
|
| 250 |
|
|
|a Final (with redactions)
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c 2020, January 2020
|
| 300 |
|
|
|a 1 PDF file (89 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Peptides / therapeutic use
|
| 653 |
|
|
|a Gastrointestinal Agents / therapeutic use
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Short Bowel Syndrome / drug therapy
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK564569
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The objective of the current CDR review was to perform a systematic review of the beneficial and harmful effects of teduglutide subcutaneous injection (Revestive) for the treatment of pediatric patients one year of age and above with Short bowel syndrome who are dependent on parenteral support
|